Portal Vein Tumor Thrombus in Hepatocellular Carcinoma: An Immune Sanctuary Driving Immune Exclusion and Therapeutic Resistance.
- 1Department of Hepatobiliary Surgery, Peking University People's Hospital, Beijing, China.
- 2Peking University Research Center for Diagnosis and Treatment of Liver Cancer, Beijing, China.
- 3Peking University Institute of Organ Transplantation, Beijing, China.
Abstract
Background
Portal vein tumor thrombus (PVTT) is the most common form of macrovascular invasion in hepatocellular carcinoma (HCC) and is associated with poor prognosis, rapid intrahepatic dissemination, and limited responsiveness to systemic therapy. Increasing evidence indicates that PVTT is not merely an intravascular extension of the primary tumor, but rather a biologically distinct and highly adaptive immunosuppressive niche that contributes to immune escape and therapeutic resistance.Summary
This review summarizes current genomic, transcriptomic, single-cell, and spatially resolved evidence regarding the immune landscape of PVTT in HCC. We discuss how early clonal divergence, hypoxia-associated metabolic rewiring, and stromal-vascular remodeling cooperatively shape the PVTT microenvironment. PVTT is characterized by enrichment of suppressive myeloid populations, activation of cancer-associated fibroblast programs, extracellular matrix accumulation, endothelial barriers to immune-cell trafficking, and progressive dysfunction or exclusion of effector lymphocytes. Together, these features establish a strongly immune-excluded and immunosuppressive ecosystem, providing a mechanistic basis for the limited efficacy of immune checkpoint blockade in patients with HCC-PVTT. We further highlight the translational implications of this framework for biomarker development, patient stratification, and rational combination strategies targeting suppressive myeloid and stromal programs, vascular barriers, and metabolic-immune crosstalk.Key messages
PVTT should be regarded as a distinct immunosuppressive niche rather than a passive vascular extension of the primary tumor. Its immune landscape is shaped by coordinated interactions among tumor evolution, metabolic adaptation, stromal remodeling, and immune dysfunction. A better mechanistic understanding of PVTT may support biomarker-guided stratification and the development of more effective precision therapies for HCC with macrovascular invasion.
Related
- CD36-Mediated Lipid Metabolic Reprogramming in Hepatocellular Carcinoma: Crosstalk With Immunity, Ferroptosis, and Therapeutic Resistance.
- Same organ, divergent immunity: T-cell exhaustion versus stromal exclusion in hepatocellular carcinoma and intrahepatic cholangiocarcinoma
- Radiotherapy Reprograms CCR8⁺ Regulatory T Cells via REL-NF-κB to Enforce Spatial Immune Exclusion in Hepatocellular Carcinoma.
- The CYB5R3–mARC1 Redox Axis in Metabolic Dysfunction-associated Steatotic Liver Disease: Mechanistic Basis and Therapeutic Prospects across the Steatosis–Cirrhosis–Hepatocellular Carcinoma Spectrum
- Therapeutic potential of natural product polysaccharides in hepatocellular carcinoma: from microenvironment modulation to combination strategies
BibTeX
@article{li2026portal,
title = {{Portal Vein Tumor Thrombus in Hepatocellular Carcinoma: An Immune Sanctuary Driving Immune Exclusion and Therapeutic Resistance.}},
author = {Xingfei Li and Qian Cheng and Jiye Zhu and Zhigao Yuan and Shaowei Mu and Tong Zhou and Jie Gao},
journal = {Liver cancer},
year = {2026},
month = sep,
doi = {10.1159/lic/admag011},
url = {https://europepmc.org/article/MED/42909923},
note = {CC BY-NC},
}
RIS
TY - JOUR
TI - Portal Vein Tumor Thrombus in Hepatocellular Carcinoma: An Immune Sanctuary Driving Immune Exclusion and Therapeutic Resistance.
AU - Xingfei Li
AU - Qian Cheng
AU - Jiye Zhu
AU - Zhigao Yuan
AU - Shaowei Mu
AU - Tong Zhou
AU - Jie Gao
PY - 2026
DA - 2026/09/12
JO - Liver cancer
DO - 10.1159/lic/admag011
UR - https://europepmc.org/article/MED/42909923
AB - Background Portal vein tumor thrombus (PVTT) is the most common form of macrovascular invasion in hepatocellular carcinoma (HCC) and is associated with poor prognosis, rapid intrahepatic dissemination, and limited responsiveness to systemic therapy. Increasing evidence indicates that PVTT is not merely an intravascular extension of the primary tumor, but rather a biologically distinct and highly adaptive immunosuppressive niche that contributes to immune escape and therapeutic resistance.Summary This review summarizes current genomic, transcriptomic, single-cell, and spatially resolved evidence regarding the immune landscape of PVTT in HCC. We discuss how early clonal divergence, hypoxia-associated metabolic rewiring, and stromal-vascular remodeling cooperatively shape the PVTT microenvironment. PVTT is characterized by enrichment of suppressive myeloid populations, activation of cancer-associated fibroblast programs, extracellular matrix accumulation, endothelial barriers to immune-cell trafficking, and progressive dysfunction or exclusion of effector lymphocytes. Together, these features establish a strongly immune-excluded and immunosuppressive ecosystem, providing a mechanistic basis for the limited efficacy of immune checkpoint blockade in patients with HCC-PVTT. We further highlight the translational implications of this framework for biomarker development, patient stratification, and rational combination strategies targeting suppressive myeloid and stromal programs, vascular barriers, and metabolic-immune crosstalk.Key messages PVTT should be regarded as a distinct immunosuppressive niche rather than a passive vascular extension of the primary tumor. Its immune landscape is shaped by coordinated interactions among tumor evolution, metabolic adaptation, stromal remodeling, and immune dysfunction. A better mechanistic understanding of PVTT may support biomarker-guided stratification and the development of more effective precision therapies for HCC with macrovascular invasion.
SN - 2235-1795
SN - 1664-5553
ER -